The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results form clinical trials. The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, the pharmaceutical industry, and to investigators in immunology and rheumatology.